Skip to main content Accessibility help
×
Home
  • Print publication year: 2004
  • Online publication date: August 2009

13 - Hypertension and stroke

from Part III - Disease prevention

Summary

There are various types of essential hypertension, as there is a variety of genetic patterns, including no patterns. The causes of hypertension include alcohol abuse, renal vascular and parenchymal disease, and certain endocrine states, including pheochromocytoma, Cushing's syndrome, and primary aldosteronism. The primary treatment of hypertension definitely starts with lifestyle changes, especially in individuals with borderline hypertension. Concomitant diseases can make high blood pressure difficult to control. Strokes are one of the most important causes of disability and the second most common cause of death worldwide. Primary prevention focuses on reducing risk factors for stroke. The six most important factors are hypertension, atrial fibrillation, history of recent myocardial infarction, diabetes, cigarette smoking, and alcohol abuse. Primary and secondary prevention of stroke by lifestyle changes, control of hypertension and diabetes, and therapeutic use of aspirin, warfarin, or angiotensin-converting enzyme inhibitors (ACEIs) will prevent further morbidity and mortality.
REFERENCES
Brown, M. J.Science, medicine and the future. Hypertension. Br. Med. J. 1997; 314:1258
O'Rorke, J. E. and Richardson, W. S.Evidence based management of hypertension: what to do when blood pressure is difficult to control. Br. Med. J. Br. Med. J.; 322:1229–32
Mercuro, G., Sonco, S., Pilia, I., et al.Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am. J. Cardiol. 1997; 80:652–7
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH publication no. 98-4080. Bethesda, MD: National Institutes of Health; 1997
Little, P., Barnett, J., Barnsley, L., et al.Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood pressure. Br. Med. J. 200; 325:254–7
Gueyffier, F., Boutitie, F., Boissel, J. P., et al.Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Ann. Intern. Med.Ann. Intern. Med.; 126:761–7
Huang, Z., Willett, W. C., Mason, J. E., et al.Body weight, weight change and the risk for hypertension in women. Ann. Intern. Med.Ann. Intern. Med.; 128:81–8
Geleijnse, J. M., Wetteman, J. C., Back, A. A., Breijen, J. H. and Grobee, D. E.Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. Br. Med. J. Br. Med. J.; 309:436–40
Ramsay, L., Williams, B., Johnston, G., et al.Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J. Hum. Hypertens. 1999; 13:569–92
Williams, B.Drug treatment of hypertension. Br. Med. J. USA 2003; 322:127–9
Mulrow, C. D. and Pignone, M.Evidence based management of hypertension: what are the elements of good treatment for hypertension?Br. Med. J. 2001; 322:1107–9
Bosch, J., Yusuf, S., Pogue, J., et al.Use of ramipril in preventing stroke: double blind randomised trial. Br. Med. J. 2002; 324:699–702
Mogensen, C. E., Neldam, S., Tikkanen, I., et al.Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. 2000; 321:1440–44
Hansson, L., Lindholm, L. H., Ekbom, T., et al.Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751–6
Collaboration Blood Pressure Lowering Treatment Trialists. Effects of angiotensin converting enzyme inhibitors, calcium antagonists and other blood pressure lowering drugs on mortality and major cardiovascular morbidity. Lancet 2000; 356:1955–64
The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomly assigned to doxazosin vs chlorthalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). J. Am. Med. Assoc. 2002; 283:1967–75
Williams, B.Drug treatment of hypertension. Br. Med. J. 2003; 326:61–2
Pope, J. E., Anderson, J. J. and Felson, D. T.A metaanalysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern. Med. 1992; 153:477–84
Johnson, A. G., Nguyen, T. V. and Day, R. O.Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann. Intern. Med. 1994; 121:289–90
Gubitz, G. and Sandercock, P.Prevention of ischaemic stroke. Br. Med. J. 2000; 321:1455–9
Alberts, M. tPA in acute ischemic stroke. United States experience and issues for the future. Neurology 1988; 51 (supp 3):53–5S
Lees, K. R., Bath, P. M. W. and Naylor, A. R.ABC of arterial and venous disease: secondary prevention of transient ischaemic attack and stroke. Br. Med. J. 2000; 320:991–4
Gorelick, P. B., Sacco, R. L., Smith, D. B.et al.Prevention of a first stroke. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. J. Am. Med. Assoc. 1999; 281:1112–20
Hart, R. G., Benavente, O., McBride, R. and Pearce, L. A.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 1999; 131:492–501
PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design of PROGRESS. J. Hypertens. 1996; 14 (supp 2):41–6S
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 1994; 308:81–106
The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group. A randomised trial of anticoagulant versus aspirin after cerebral ischemia of presumed arterial origin. Ann. Neurol. 1997; 42:857–65
Hart, R. G., Benavente, O., McBride, R. and Pearce, L. A.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta analysis. Ann. Intern. Med. 1999; 131:492–501
Cina, C., Clase, C. and Haynes, R. Carotid endarterectomy for symptomatic stenosis. In: Cochrane Library, Issue 3. Oxford: Update Software; 1999